Inherited gastrointestinal stromal tumor syndromes: mutations, clinical features, and therapeutic implications

por Postow, Michael A, Robson, Mark E
Publicado 2012

Routine clinical parameters and laboratory testing predict therapy-related myeloid neoplasms after treatment for breast cancer

por Petrone, Giulia, Gaulin, Charles, Derkach, Andriy, Kishtagari, Ashwin, Robson, Mark E., Parameswaran, Rekha, Stein, Eytan M.
Publicado 2022

Deep Interactive Learning-based ovarian cancer segmentation of H&E-stained whole slide images to study morphological patterns of BRCA mutation

por Ho, David Joon, Chui, M. Herman, Vanderbilt, Chad M., Jung, Jiwon, Robson, Mark E., Park, Chan-Sik, Roh, Jin, Fuchs, Thomas J.
Publicado 2022

Development of a novel measure of advanced cancer patients’ perceived utility of secondary germline findings from tumor genomic profiling

por Hamilton, Jada G., Shah, Ibrahim H., Salafia, Caroline, Schofield, Elizabeth, Garzon, Margaux Genoff, Cadet, Kechna, Stadler, Zsofia K., Hay, Jennifer L., Offit, Kenneth, Robson, Mark E.
Publicado 2023

Improving our model of cascade testing for hereditary cancer risk by leveraging patient peer support: a concept report

por O’Neill, Suzanne C., Hamilton, Jada G., Conley, Claire C., Peshkin, Beth N., Sacca, Rosalba, McDonnell, Glynnis A., Isaacs, Claudine, Robson, Mark E., Tercyak, Kenneth P.
Publicado 2021

A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment

por Robson, Mark E, Chappuis, Pierre O, Satagopan, Jaya, Wong, Nora, Boyd, Jeff, Goffin, John R, Hudis, Clifford, Roberge, David, Norton, Larry, Bégin, Louis R, Offit, Kenneth, Foulkes, William D
Publicado 2004

Interest and Utility of MC1R Testing for Melanoma Risk in Dermatology Patients with a History of Nonmelanoma Skin Cancer

por Hay, Jennifer L., Lee, Erica H., Christian, Stephanie N., Schofield, Elizabeth, Hamilton, Jada G., Yang, Ciyu, Hedayati, Bobak, Sadeghi, Keimya, Robson, Mark E., Halpern, Allan, Zhang, Liying, Orlow, Irene
Publicado 2022

Conflicting Interpretation of Genetic Variants and Cancer Risk by Commercial Laboratories as Assessed by the Prospective Registry of Multiplex Testing

por Balmaña, Judith, Digiovanni, Laura, Gaddam, Pragna, Walsh, Michael F., Joseph, Vijai, Stadler, Zsofia K., Nathanson, Katherine L., Garber, Judy E., Couch, Fergus J., Offit, Kenneth, Robson, Mark E., Domchek, Susan M.
Publicado 2016

Genetic Analysis of the Early Natural History of Epithelial Ovarian Carcinoma

por Pothuri, Bhavana, Leitao, Mario M., Levine, Douglas A., Viale, Agnès, Olshen, Adam B., Arroyo, Crispinita, Bogomolniy, Faina, Olvera, Narciso, Lin, Oscar, Soslow, Robert A., Robson, Mark E., Offit, Kenneth, Barakat, Richard R., Boyd, Jeff
Publicado 2010

The Landscape of Somatic Genetic Alterations in Breast Cancers from CHEK2 Germline Mutation Carriers

por Mandelker, Diana, Kumar, Rahul, Pei, Xin, Selenica, Pier, Setton, Jeremy, Arunachalam, Sasi, Ceyhan-Birsoy, Ozge, Brown, David N, Norton, Larry, Robson, Mark E, Wen, Hannah Y, Powell, Simon, Riaz, Nadeem, Weigelt, Britta, Reis-Filho, Jorge S
Publicado 2019

Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab

por Ferraro, Emanuela, Singh, Jasmeet, Patil, Sujata, Razavi, Pedram, Modi, Shanu, Chandarlapaty, Sarat, Barrio, Andrea V., Malani, Rachna, Mellinghoff, Ingo K., Boire, Adrienne, Wen, Hannah Y., Brogi, Edi, Seidman, Andrew D., Norton, Larry, Robson, Mark E., Dang, Chau T.
Publicado 2022

Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testing

por Cheng, Donavan T., Prasad, Meera, Chekaluk, Yvonne, Benayed, Ryma, Sadowska, Justyna, Zehir, Ahmet, Syed, Aijazuddin, Wang, Yan Elsa, Somar, Joshua, Li, Yirong, Yelskaya, Zarina, Wong, Donna, Robson, Mark E., Offit, Kenneth, Berger, Michael F., Nafa, Khedoudja, Ladanyi, Marc, Zhang, Liying
Publicado 2017

Cascading After Peridiagnostic Cancer Genetic Testing: An Alternative to Population-Based Screening

por Offit, Kenneth, Tkachuk, Kaitlyn A., Stadler, Zsofia K., Walsh, Michael F., Diaz-Zabala, Hector, Levin, Jeffrey D., Steinsnyder, Zoe, Ravichandran, Vignesh, Sharaf, Ravi N., Frey, Melissa K., Lipkin, Steven M., Robson, Mark E., Hamilton, Jada G., Vijai, Joseph, Mukherjee, Semanti
Publicado 2020

The genomic landscape of metastatic histologic special types of invasive breast cancer

por Pareja, Fresia, Ferrando, Lorenzo, Lee, Simon S. K., Beca, Francisco, Selenica, Pier, Brown, David N., Farmanbar, Amir, Da Cruz Paula, Arnaud, Vahdatinia, Mahsa, Zhang, Hong, Zoppoli, Gabriele, Wen, Hannah Y., Brogi, Edi, Robson, Mark E., Razavi, Pedram, Chandarlapaty, Sarat, Weigelt, Britta, Reis-Filho, Jorge S.
Publicado 2020

Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO study

por Turner, Nicholas C., Laird, A. Douglas, Telli, Melinda L., Rugo, Hope S., Mailliez, Audrey, Ettl, Johannes, Grischke, Eva-Maria, Mina, Lida A., Balmaña, Judith, Fasching, Peter A., Hurvitz, Sara A., Hopkins, Julia F., Albacker, Lee A., Chelliserry, Jijumon, Chen, Ying, Conte, Umberto, Wardley, Andrew M., Robson, Mark E.
Publicado 2023

Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action

por Cairns, Junmei, Ingle, James N., Dudenkov, Tanda M., Kalari, Krishna R., Carlson, Erin E., Na, Jie, Buzdar, Aman U., Robson, Mark E., Ellis, Matthew J., Goss, Paul E., Shepherd, Lois E., Goodnature, Barbara, Goetz, Matthew P., Weinshilboum, Richard M., Li, Hu, Bari, Mehrab Ghanat, Wang, Liewei
Publicado 2020

Integrating Clinical and Polygenic Factors to Predict Breast Cancer Risk in Women Undergoing Genetic Testing

por Hughes, Elisha, Tshiaba, Placede, Wagner, Susanne, Judkins, Thaddeus, Rosenthal, Eric, Roa, Benjamin, Gallagher, Shannon, Meek, Stephanie, Dalton, Kathryn, Hedegard, Wade, Adami, Carol A., Grear, Danna F., Domchek, Susan M., Garber, Judy, Lancaster, Johnathan M., Weitzel, Jeffrey N., Kurian, Allison W., Lanchbury, Jerry S., Gutin, Alexander, Robson, Mark E.
Publicado 2021

Genome doubling shapes the evolution and prognosis of advanced cancers

por Bielski, Craig M., Zehir, Ahmet, Penson, Alexander V., Donoghue, Mark T.A., Chatila, Walid, Armenia, Joshua, Chang, Matthew T., Schram, Alison M., Jonsson, Philip, Bandlamudi, Chaitanya, Razavi, Pedram, Iyer, Gopa, Robson, Mark E., Stadler, Zsofia K., Schultz, Nikolaus, Baselga, Jose, Solit, David B., Hyman, David M., Berger, Michael F., Taylor, Barry S.
Publicado 2018

Uptake and acceptability of a mainstreaming model of hereditary cancer multigene panel testing among patients with ovarian, pancreatic, and prostate cancer

por Hamilton, Jada G., Symecko, Heather, Spielman, Kelsey, Breen, Kelsey, Mueller, Rebecca, Catchings, Amanda, Trottier, Magan, Salo-Mullen, Erin E., Shah, Ibrahim, Arutyunova, Anna, Batson, Melissa, Gebert, Rebecca, Pundock, Stacy, Schofield, Elizabeth, Offit, Kenneth, Stadler, Zsofia, Cadoo, Karen, Carlo, Maria I., Narayan, Vivek, Reiss, Kim A., Robson, Mark E., Domchek, Susan M.
Publicado 2021

Anastrozole Aromatase Inhibitor Plasma Drug Concentration Genome‐Wide Association Study: Functional Epistatic Interaction Between SLC38A7 and ALPPL2

por Dudenkov, Tanda M., Liu, Duan, Cairns, Junmei, Devarajan, Sandhya, Zhuang, Yongxian, Ingle, James N., Buzdar, Aman U., Robson, Mark E., Kubo, Michiaki, Batzler, Anthony, Barman, Poulami, Jenkins, Gregory D., Carlson, Erin E., Goetz, Matthew P., Northfelt, Donald W., Moreno‐Aspitia, Alvaro, Desta, Zeruesenay, Reid, Joel M., Kalari, Krishna R., Wang, Liewei, Weinshilboum, Richard M.
Publicado 2019